Literature DB >> 29255070

How I treat disseminated intravascular coagulation.

Marcel Levi1,2, Marie Scully2,3.   

Abstract

Disseminated intravascular coagulation (DIC) is a condition characterized by systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, thereby contributing to organ dysfunction. At the same time, ongoing consumption of platelets and coagulation proteins results in thrombocytopenia and low concentrations of clotting factors, which may cause profuse hemorrhagic complications. DIC is always secondary to an underlying condition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamities. A reliable diagnosis of DIC can be made through simple scoring algorithms based on readily available routine hemostatic parameters. The cornerstone of supportive treatment of this coagulopathy is management of the underlying condition. Additionally, administration of heparin may be useful, and restoration of physiological anticoagulants has been suggested, but has not been proven successful in improving clinically relevant outcomes so far. In patients with major bleeding or at risk for hemorrhagic complications, administration of platelet concentrates, plasma, or coagulation factor concentrates should be considered.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29255070     DOI: 10.1182/blood-2017-10-804096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death.

Authors:  Robert Silasi; Ravi Shankar Keshari; Cristina Lupu; Walter Janse Van Rensburg; Hala Chaaban; Girija Regmi; Aleksandr Shamanaev; Joseph J Shatzel; Cristina Puy; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Florea Lupu
Journal:  Blood Adv       Date:  2019-02-26

2.  Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation.

Authors:  Emily P Mihalko; Megan Sandry; Nicholas Mininni; Kimberly Nellenbach; Halston Deal; Michael Daniele; Kamrouz Ghadimi; Jerrold H Levy; Ashley C Brown
Journal:  Blood Adv       Date:  2021-02-09

3.  Repurposed Tocilizumab in Patients with Severe COVID-19.

Authors:  Jianbo Tian; Ming Zhang; Meng Jin; Fengqin Zhang; Qian Chu; Xiaoyang Wang; Can Chen; Huihui Yue; Li Zhang; Ronghui Du; Dong Zhao; Zhaofu Zeng; Yang Zhao; Kui Liu; Mengmei Wang; Ke Hu; Xiaoping Miao; Huilan Zhang
Journal:  J Immunol       Date:  2020-12-09       Impact factor: 5.422

4.  COVID-19 and venous thromboembolism: current insights and prophylactic strategies.

Authors:  Pasquale Ambrosino; Alessandro Di Minno; Mauro Maniscalco; Matteo Nicola Dario Di Minno
Journal:  Ann Med       Date:  2020-07-13       Impact factor: 4.709

5.  Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19.

Authors:  Tanya K Marvi; William B Stubblefield; Benjamin F Tillman; Mark W Tenforde; Manish M Patel; Christopher J Lindsell; Wesley H Self; Carlos G Grijalva; Todd W Rice
Journal:  Crit Care Explor       Date:  2022-01-18

6.  The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients.

Authors:  Ronit Mor-Cohen; Michal Zucker; Colin Grissom; Samuel M Brown; Uri Seligsohn; Robert A Campbell; Antoinette M Blair; Matthew T Rondina
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

7.  Prothrombotic and Proinflammatory Activities of the β-Hemolytic Group B Streptococcal Pigment.

Authors:  Nikolai Siemens; Sonja Oehmcke-Hecht; Jörn Hoßmann; Sebastian B Skorka; Roel H T Nijhuis; Corinne Ruppen; Steinar Skrede; Manfred Rohde; Daniel Schultz; Michael Lalk; Andreas Itzek; Dietmar H Pieper; Christiaan J van den Bout; Eric C J Claas; Ed J Kuijper; Robert Mauritz; Parham Sendi; Herman F Wunderink; Anna Norrby-Teglund
Journal:  J Innate Immun       Date:  2019-11-19       Impact factor: 7.349

8.  Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation.

Authors:  Ashley C Brown; Jerrold H Levy
Journal:  Anesthesiology       Date:  2019-09       Impact factor: 7.892

9.  Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness.

Authors:  William E Plautz; Zachary A Matthay; Marian A Rollins-Raval; Jay S Raval; Lucy Z Kornblith; Matthew D Neal
Journal:  Transfusion       Date:  2020-06-01       Impact factor: 3.157

Review 10.  Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19.

Authors:  Marcel Levi
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.